Finance

Lists
Why is BCYC up 3.32%?
Dive Deeper
BCYC:NASDAQ
Bicycle Therapeutics PLC
$3.58
+3.32%
(+0.12) 1D
Oct 19, 11:21:06 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BCYC...
Open
$3.45
High
$3.63
Low
$3.41
Mkt. cap
250.22M
Avg. vol.
505.62K
Volume
167.13K
52-wk high
$9.08
52-wk low
$3.33
EPS
-$2.74
Beta
1.68
Shares outstanding
50.56M
No. of employees
288
Open
$3.45
High
$3.63
Low
$3.41
Mkt. cap
250.22M
Avg. vol.
505.62K
Volume
167.13K
52-wk high
$9.08
52-wk low
$3.33
EPS
-$2.74
Beta
1.68
Shares outstanding
50.56M
No. of employees
288
News stories
From web sources and news partners
About Bicycle Therapeutics PLC
CEOKevin Lee
Employees288
Founded2009
Headquarters-
SectorBiotechnology
Websitebicycletherapeutics.com
Analyst ratings
Based on 6 analysts giving stock ratings to BCYC in the past 3 months
Buy
Buy
3
Hold
3
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for BCYC in the last 3 months.
Highest
Current $3.58
$14.00 (+291.61%)
Average
$9.25 (+158.74%)
Lowest
$5.00 (+39.86%)
Analyst
Recommendation
Action
Price target
Projected
Date
Maxwell Skor
Morgan Stanley
Hold
Maintained
-
-
08/17/2026
Jeff Jones
Oppenheimer
Buy
Initiated
$11.00
+207.7%
07/31/2026
Gregory Renza
Truist Financial
Hold
Maintained
$7.00
+95.8%
07/31/2026
Tara Bancroft
TD Cowen
Buy
Maintained
-
-
07/30/2026
Ami Fadia
Needham
Buy
Maintained
$14.00
+291.6%
07/30/2026
Leonid Timashev
RBC Capital
Hold
Maintained
$5.00
+39.9%
07/30/2026
Maury Raycroft
Jefferies
Buy
Maintained
$12.00
+235.7%
04/30/2026
Jay Olson
Oppenheimer
Buy
Maintained
$36.00
+907%
03/18/2026
Reni Benjamin
Citizens JMP
Buy
Maintained
$8.00
+123.8%
03/18/2026
Next call in 10 days
Thu, Oct 29, 1:00 PM
Fiscal period
Q3 2026
- / -$0.46
Revenue / Est. (USD)
- / 12.20M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
11.73M
47.96M
887.00K
629.00K
Cost of goods sold
56.61M
45.92M
46.96M
41.16M
Cost of revenue
56.61M
45.92M
46.96M
41.16M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
20.67M
22.55M
19.41M
14.03M
Operating expense
20.67M
22.55M
19.41M
14.03M
Total operating expenses
77.28M
68.46M
66.37M
55.19M
Operating income
-65.55M
-20.51M
-65.48M
-54.56M
Other non operating income
-
-
-
-
EBT including unusual items
-58.90M
-18.89M
-60.65M
-50.24M
EBT excluding unusual items
-58.90M
-14.69M
-60.65M
-50.24M
Income tax expense
205.00K
1.26M
172.00K
90.00K
Effective tax rate
-0.35%
-6.70%
-0.28%
-0.18%
Other operating expenses
-
-
-
-
Net income
-59.10M
-20.15M
-60.82M
-50.33M
Net profit margin
-503.66%
-42.03%
-6,857.38%
-8,002.07%
Earnings per share
-0.85
-0.29
-0.87
-0.72
Interest and investment income
6.70M
5.88M
4.88M
4.36M
Interest expense
-44.00K
-57.00K
-48.00K
-44.00K
Net interest expenses
6.66M
5.82M
4.83M
4.32M
Depreciation and amortization charges
-
-
-
-
EBITDA
-63.80M
-19.17M
-64.35M
-53.49M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps